Purpose

This is a multi-center Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). It is double-blinded, meaning that the Sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.

Condition

Eligibility

Eligible Ages
Between 18 Years and 65 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted. - At least 50% scalp hair loss, as defined by a SALT score ≥50, at Screening and Baseline. - Willing to comply with the study visits and requirements of the study protocol.

Exclusion Criteria

  • Treatment with other medications or agents within 1 month of Baseline or during the study that may affect hair regrowth or immune response. - Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or other scalp condition that may interfere with the SALT assessment, or untreated actinic keratosis anywhere on the body at Screening and/or Baseline. - Treatment with systemic immunosuppressive medications within 3 months of Screening or during the study, or biologics within 6 months of Screening or during the study. - Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug. - Clinically significant medical condition, psychiatric disease, or social condition, as determined by the Investigator, that may unfavorably alter the risk-benefit of study participation, adversely affect study compliance, or confound interpretation of study results.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
CTP-543, 8 mg BID
Oral tablet for 24 weeks
  • Drug: CTP-543, 8 mg BID
    8 mg twice-daily (BID)
Experimental
CTP-543, 12 mg BID
Oral tablet for 24 weeks
  • Drug: CTP-543, 12 mg BID
    12 mg twice-daily (BID)
Placebo Comparator
Placebo, BID
Oral tablet for 24 weeks
  • Drug: Placebo, BID
    Placebo, twice-daily (BID)

Recruiting Locations

Massachusetts General Hospital - Clinic
Boston, Massachusetts 02114

More Details

Status
Recruiting
Sponsor
Concert Pharmaceuticals

Study Contact

Colleen E. Hamilton, MS
781-860-0045
AAclinicaltrial_inquiries@concertpharma.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.